Spyryx Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.spyryxbio.com
An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Placebo Inhalation Solution
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Spyryx Biosciences, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT03229252
- Locations
- 🇨🇦
Ottawa Hospital Research Institute/Institut de Recherche de l'Hospital d'Ottawa, Ottawa, Ontario, Canada
🇫🇷CHU de Rouen, Rouen, Haute-Normandie, France
🇫🇷CHU de Angers, Angers, Pays De La Loire, France
A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Spyryx Biosciences, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03056989
- Locations
- 🇨🇦
Saint Michael's Hospital, Toronto, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath